



5.30.67

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	1 of 7

Last Review Date: June 16, 2022

Leuprolide

Description

leuprolide acetate 1mg/0.2mL

Eligard, Fensolvi, Lupron Depot (leuprolide acetate)

Camcevi* (leuprolide mesylate)

*This medication is included in this policy but not available on the market as of yet

Background

Leuprolide, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Human studies indicate that following an initial stimulation of gonadotropins, chronic stimulation with leuprolide results in suppression or “downregulation” of these hormones and consequent suppression of ovarian and testicular steroidogenesis. These effects are reversible on discontinuation of drug therapy (1-7).

Regulatory Status

FDA-approved indications: (1-7)

- Camcevi is indicated for the treatment of adult patients with advanced prostate cancer.
- Eligard is indicated for the palliative treatment of advanced prostate cancer.
- Fensolvi is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).
- Leuprolide acetate 1mg/0.2mL for subcutaneous injection is indicated:
 - In the palliative treatment of advanced prostatic cancer
- Lupron Depot is indicated:

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	2 of 7

- For the management of endometriosis, including pain relief and reduction of endometriotic lesions.
- With iron therapy before fibroid surgery to improve anemia from fibroids.
- For the treatment of advanced prostate cancer.
- For the treatment of children with central precocious puberty (CPP).

Off-Label Uses: (8)

- Breast cancer

NCCN recommends the use of Lupron Depot in males and females with breast cancer (8).

The safety and effectiveness of leuprolide for CPP in pediatric patients less than 2 years of age have not been established. The safety and effectiveness of leuprolide for advanced prostate cancer in pediatric patients less than 18 years of age have not been established. The safety and effectiveness of Lupron Depot for the management of endometriosis and hematologic improvement of women with anemia caused by fibroids have been established in females of reproductive age (1-7).

Related policies

ART Drugs, HCG, Synarel

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Leuprolide may be considered **medically necessary** for patients with advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, breast cancer, or gender dysphoria and if the conditions indicated below are met.

Leuprolide may be considered **investigational** for all other indications.

Prior-Approval Requirements

Diagnoses

Female

Patient must have **ONE** of the following:

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	3 of 7

1. Fensolvi **only:**
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
2. Lupron Depot **only:**
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
 - b. Endometriosis
 - c. Uterine fibroids
 - d. Breast cancer

Male

Patient must have **ONE** of the following:

1. Camcevi, Eligard and leuprolide acetate 1mg/0.2mL **only:**
 - a. Advanced prostate cancer
 - a. 18 years of age or older
2. Fensolvi **only:**
 - a. Central precocious puberty (CPP)
 - a. 2 years of age or older
3. Lupron Depot **only:**
 - a. Central precocious puberty (CPP)
 - a. 2 years of age or older
 - b. Advanced prostate cancer
 - a. 18 years of age or older
 - c. Breast cancer

AND NOT used for the following for both males and females:

1. Weight loss
2. Anti-aging effects
3. Performance (athletic) enhancement
4. Erectile or sexual dysfunction

Diagnosis

The patient must have the following:

Gender Dysphoria (GD)

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	4 of 7

1. Prescribed by an endocrinologist or transgender specialist
2. Patient has met the DSM V criteria for GD

Prior – Approval *Renewal* Requirements

Diagnoses

Female

Patient must have **ONE** of the following:

1. Fensolvi **only**:
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
2. Lupron Depot **only**:
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
 - b. Endometriosis
 - c. Uterine fibroids
 - d. Breast cancer

Male

Patient must have **ONE** of the following:

1. Camcevi, Eligard and leuprolide acetate 1mg/0.2mL **only**:
 - a. Advanced prostate cancer
 - i. 18 years of age or older
2. Fensolvi **only**:
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
3. Lupron Depot **only**:
 - a. Central precocious puberty (CPP)
 - i. 2 years of age or older
 - b. Advanced prostate cancer
 - i. 18 years of age or older
 - c. Breast cancer

AND NOT used for the following for both males and females:

1. Weight loss

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	5 of 7

2. Anti-aging effects
3. Performance (athletic) enhancement
4. Erectile or sexual dysfunction

Diagnosis

The patient must have the following:

Gender Dysphoria (GD)

1. Prescribed by an endocrinologist or transgender specialist

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration	Females	6 months
	Males	12 months
	GD	2 years

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Leuprolide, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when given continuously and in therapeutic doses. Human studies indicate that following an initial stimulation of gonadotropins, chronic stimulation with leuprolide results in suppression or “downregulation” of these hormones and consequent suppression of ovarian and testicular steroidogenesis. These effects are reversible on discontinuation of drug therapy. Leuprolide is used in the treatment of advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, breast cancer, or gender dysphoria. The safety and effectiveness of leuprolide for CPP in pediatric patients less than 2 years of age have not been established. The

Section:	Prescription Drugs	Effective Date:	July 1, 2022
Subsection:	Endocrine and Metabolic Drugs	Original Policy Date:	May 29, 2020
Subject:	Leuprolide	Page:	6 of 7

safety and effectiveness of leuprolide for advanced prostate cancer in pediatric patients less than 18 years of age have not been established. The safety and effectiveness of Lupron Depot for the management of endometriosis and hematologic improvement of women with anemia caused by fibroids have been established in females of reproductive age (1-7).

Prior approval is required to ensure the safe, clinically appropriate and cost-effective use of leuprolide while maintaining optimal therapeutic outcomes.

References

1. Camcevi [package insert]. Taipei City, Taiwan: Foresee Pharmaceuticals Co., Ltd.; May 2021.
2. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; April 2019.
3. Fensolvi [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; March 2022.
4. Leuprolide Acetate Injection [package insert]. Princeton, NJ: Sandoz Inc.; June 2020.
5. Lupron Depot GYN [package insert]. North Chicago, IL: AbbVie Inc.; February 2021.
6. Lupron Depot URO [package insert]. North Chicago, IL: AbbVie Inc.; April 2022.
7. Lupron Depot-PED [package insert]. North Chicago, IL: AbbVie Inc.; March 2021.
8. NCCN Drugs & Biologics Compendium® Leuprolide Acetate 2022. National Comprehensive Cancer Network, Inc. Accessed on April 21, 2022.

Policy History

Date	Action
May 2020	Addition to PA
September 2020	Annual review
November 2020	Addition of off-label indication for Lupron Depot per NCCN: breast cancer
March 2021	Annual review and reference update
July 2021	Addition of Camcevi to policy. Renamed policy Leuprolide
August 2021	Added leuprolide acetate 1mg/0.2mL to the header and criteria to assist in differentiating between generic (non-depot) Lupron and other leuprolide products
September 2021	Annual review and reference update
June 2022	Annual editorial review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 16, 2022 and is effective on July 1, 2022.